演題詳細

ポスター / Poster

ポスター 35 (Poster 35) :骨髄腫:症例(レナリドミド)

print

日程
2013年10月11日(金)
時間
16:50 - 17:50
会場
ポスター会場 / Poster (ロイトン札幌 3F ロイトンホールABCD)
座長・司会
和泉 透 (Tohru Izumi):1
1:栃木県立がんセンター 血液内科
 
前へ戻る

A case report: Bor, Len, and Dex combination as re-induction therapy in transplant-eligible patient

演題番号 : PS-1-265

杠 明憲 (Akinori Yuzuriha):1,2、斎藤 明生 (Akio Saitou):1、馬渡 桃子 (Momoko Mawatari):1、磯田 淳 (Atsushi Isoda):1、松本 守生 (Morio Matsumoto):1、澤村 守夫 (Morio Sawamura):1

1:Nishigunma National Hospital、2:Gunma University Graduate School of Medicine

 

[Introduction]Induction therapy with the combination of three drugs containing proteasome inhibitor and immunomodulatory drugs(IMiDs) has been examined for the young myeloma patients in transplant-eligible.
[Case]A 45-years-old male onset multiple myeloma with the tumor in bone marrow of right femora. The first medical examination was 3 months after the onset and he was diagnosed as MM(IgG-κ, BJP-κ, ISS I, DS IA). After the local radiation therapy for the tumor in femora, BCD (Bor 1.3mg/m2, days 1,4,8,11. + Cy 500mg/m2, days 1,8. + Dex 40mg/body, days 1,4,8,11) from day 1, and BCD (Bor 1.3mg/m2, days 1,8,15,22. + Cy 300mg/m2, days 1,8,15,22. + Dex 40mg/body, days 1,8,15,22) from day 22 were performed. As the patient became PD at day 63, BLD (Bor 1.3mg/m2, days 1,4,8,11. + Len 25mg/body, days 1-14. + Dex 20mg/body, days 1,2,4,5,8,9,11,12) were administered from day 70. After 5 of 21 days cycle, the patient gained PR. Mild peripheral neuropathy was seen as Adverse Event.
[Discussion]The patient, as a result, became PD with the induction therapy with BCD. As the efficiency of BLD reported by Richardson et al, the M-protein level was reduced and the patient became PR. Taking the possibility of myeloma cells clonal evolution into consideration, the prognostic improvement would be expected with the BLD regimen as induction therapy in early stage. However, further case studies of this regimen are needed.
[Conclusion]In the young multiple myeloma patient refractory to BCD, BLD has possibilities of an effective induction regimen with HDT-ASCT.

前へ戻る